Downloads: 80 | Views: 177
Research Paper | Medical Microbiology | India | Volume 9 Issue 10, October 2020
Seropositivity of Torch Infection in Patients with Bad Obstetrics History
Aakansha Pandey Shukla | Adityam Shukla
Abstract: Background and Objectives: Primary infection with TORCH complex [Toxoplasma, Rubella, Cytomegalovirus (CMV), and Herpes simplex virus II (HSV-II)] in pregnant women can lead to adverse outcome. The present study was undertaken to determine seropositivity of TORCH Infection in Bad obstetric history patients aged 20-46 and to investigate the correlation with sociodemographic characteristics and to find its relation with other various risk factors associated with TORCH among seropositive patients. Materials and Methods: The cross-sectional study was carried out for a period of four months in a tertiary care hospital. Total of 40 sera samples were collected at Dept. of Microbiology, IIMS & R, Lucknow from pregnant female patients attending the outdoor and indoor clinic of the department of Obstetrics & Gynaecology by using ELISA. Results: Out of the 40 pregnant female patients in the study, seropositivity of IgG/IgM in Toxoplasma gondii, Rubella, CMV, HSV was 5 (12.5 %) /2 (5 %), 21 (52.5 %) /0 (0 %), 13 (32.5 %) /0 (0 %), 21 (52.5 %) /2 (5 %) respectively. It was found that maximum 35 % patients belonged to 26-30 followed by age group 20-25 i. e.27.5 %, age group 31-36 i. e.25 % and least in age group belongs to 37-40 i. e.7.5 % and 41-46 i. e.5 %. In this study majority of the patients were belong to rural areas. Conclusion: The purpose of screening for TORCH Infection is not only to identify seropositivity, but to help seropositive people identify symptoms and protect themselves from acquiring other various risk factors and to protect their partners and seronegative people from acquiring TORCH. Of the 40 pregnant women with BOH, We recommend that all antenatal cases with such history should be routinely screened for these agents.
Keywords: TORCH, Seropositivity, Bad obstetric history, IgG, IgM, HSV, ELISA
Edition: Volume 9 Issue 10, October 2020,
Pages: 1448 - 1450